ABVCABVC BIOPHARMA, INC.

Nasdaq abvcpharma.com


$ 0.66 $ -0.05 (-7.26 %)    

Friday, 16-Aug-2024 15:58:18 EDT
QQQ $ 478.94 $ 3.28 (0.69 %)
DIA $ 408.31 $ 1.57 (0.39 %)
SPY $ 558.11 $ 3.22 (0.58 %)
TLT $ 97.96 $ 0.01 (0.02 %)
GLD $ 231.47 $ 1.27 (0.55 %)
$ 0.6594
$ 0.70 x 100
-- x --
-- - --
$ 0.60 - $ 3.35
106,826
na
8.19M
$ 0.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-17-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-16-2021 12-31-2020 10-K
15 11-17-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 06-30-2020 03-31-2020 10-Q
18 05-15-2020 12-31-2019 10-K
19 11-18-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-28-2019 03-31-2019 10-Q
22 04-15-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-20-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 01-16-2018 09-30-2017 10-K
27 08-21-2017 06-30-2017 10-Q
28 05-22-2017 03-31-2017 10-Q
29 02-21-2017 12-31-2016 10-Q
30 01-12-2017 09-30-2016 10-K
31 08-15-2016 06-30-2016 10-Q
32 05-16-2016 03-31-2016 10-Q
33 02-23-2016 12-31-2015 10-Q
34 11-27-2015 09-30-2015 10-K
35 08-19-2015 06-30-2015 10-Q
36 05-15-2015 03-31-2015 10-Q
37 04-17-2015 12-31-2013 10-Q
38 04-17-2015 03-31-2014 10-Q
39 04-17-2015 06-30-2014 10-Q
40 04-17-2015 09-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abvc-biopharma--biolite-entered-into-definitive-agreement-with-oncox-biopharma-to-collaborate-on-combination-therapy-abvc--unit-are-eligible-to-receive-aggregate-license-fee-of-125m-in-form-of-cash-or-shares-of-oncox-securities-under-terms-of-deal-abvc-grants-oncox-exclusive-rights-for-one-of-abvcs-4-products-in-its-oncology-pipeline

- SEC Filing 

 abvc-biopharma-collaboration-between-abvc-and-oncox-biopharma-abvc-expecting-aggregate-income-of-1375m-and-royalties-of-up-to-1250m-grants-oncox-exclusive-rights-for-one-of-abvcs-four-products-in-its-oncology-pipeline-to-develop-manufacture-commercialize-blex-404

https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm

 aibtl-biopharma-inc-acquired-tt-life-company-valued-at-833m-with-166m-aibtl-shares-at-5-per-share

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solut...

 abvc-biopharma-executes-a-global-licensing-definitive-agreement-for-the-treatment-of-nsclc-expecting-aggregate-income-of-1375m-and-royalties-of-up-to-1250m

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solut...

Core News & Articles
Market-Moving News for April 10th
04/10/2024 12:39:39

ADIL: 108% | Adial Pharmaceuticals shares are trading higher after the company announced the publication of a peer-reviewed art...

 abvc-biopharma-executes-a-global-licensing-term-sheet-for-oncologyhematology-products-expecting-licensing-income-of-55m-and-royalties-of-up-to-50m

 ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solu...

 why-abvc-biopharma-stock-is-up-today

ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus lic...

 abvc-biopharma-provides-fiscal-year-2024-q1-business-update

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a biotechnology company specializing in botanically based solutions tha...

 abvcs-new-horizon-for-oncology-and-hematology-aims-at-cancer-market

 ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solu...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION